Orgenesis Inc. announced it has entered into a non-binding licensing and supply agreement-in-principle with Humavox Ltd. and MirCod for the development of key technology related to biological sensing with wireless charging for Orgenesis™ clinical development and manufacturing projects. The parties expect to complete due diligence and execute a definitive agreement within 45 days. The combined technologies of Humavox and MirCod intend to further strengthen Orgenesis™ competitive edge by optimizing processes to achieve higher yields and better capture data, reduce cost and improve product quality. Orgenesis intends to develop this technology with Humavox and MirCod for its in-house clinical development programs and will further out-license the technology to its subsidiaries including MaSTherCell and affiliates. MirCod's technology enables developers to connect various sensors without complex integration and unnecessary delays for electronics integration, code writing, visualization and core hardware development. The monitoring sensor platform can measure the evolution of pH in the medium, glucose consumption, oxygen and other factors key to optimizing growth of cell cultures. Data is monitored and recorded in real-time and stored securely for further evaluation. A fully integrated approach for monitoring and powering the monitors ensures that there is no contamination because it maintains a closed environment and no loss of power to sensors.